<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34315786</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order.</ArticleTitle><Pagination><StartPage>528</StartPage><EndPage>536</EndPage><MedlinePgn>528-536</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000012545</ELocationID><Abstract><AbstractText>Development of effective treatments for amyotrophic lateral sclerosis (ALS) has been hampered by disease heterogeneity, a limited understanding of underlying pathophysiology, and methodologic design challenges. We have evaluated 2 major themes in the design of pivotal, phase 3 clinical trials for ALS-(1) patient selection and (2) analytical strategy-and discussed potential solutions with the European Medicines Agency. Several design considerations were assessed using data from 5 placebo-controlled clinical trials (n = 988), 4 population-based cohorts (n = 5,100), and 2,436 placebo-allocated patients from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. The validity of each proposed design modification was confirmed by means of simulation and illustrated for a hypothetical setting. Compared to classical trial design, the proposed design modifications reduce the sample size by 30.5% and placebo exposure time by 35.4%. By making use of prognostic survival models, one creates a potential to include a larger proportion of the population and maximize generalizability. We propose a flexible design framework that naturally adapts the trial duration when inaccurate assumptions are made at the design stage, such as enrollment or survival rate. In case of futility, the follow-up time is shortened and patient exposure to ineffective treatments or placebo is minimized. For diseases such as ALS, optimizing the use of resources, widening eligibility criteria, and minimizing exposure to futile treatments and placebo is critical to the development of effective treatments. Our proposed design modifications could circumvent important pitfalls and may serve as a blueprint for future clinical trials in this population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK. r.p.a.vaneijk-2@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolakopoulos</LastName><ForeName>Stavros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roes</LastName><ForeName>Kit C B</ForeName><Initials>KCB</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kendall</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2812-0154</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Steve S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavrov</LastName><ForeName>Arseniy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Noam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kliest</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jongh</LastName><ForeName>Adriaan D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westeneng</LastName><ForeName>Henk-Jan</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eijkemans</LastName><ForeName>Marinus J C</ForeName><Initials>MJC</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, UMC Utrecht Brain Center (R.P.A.v.E., T.K., A.D.d.J., H.-J.W., L.H.v.d.B.), and Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care (R.P.A.E., S.N., M.J.C.E.), University Medical Center Utrecht; Department of Health Evidence (K.C.B.R.), Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands; Biostatistics (L.K.), GlaxoSmithKline R&amp;D, Stevenage, UK; Neurosciences (S.S.H.), Takeda Pharmaceuticals, Cambridge, MA; Discovery Medicine (S.S.H., N.E.), GlaxoSmithKline R&amp;D, Upper Providence, PA; Clinical Development (A.L.), Novartis Gene Therapies; Clinical Translational Medicine (A.L.), Future Pipeline Discovery, GlaxoSmithKline R&amp;D, Middlesex; Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, Department of Basic and Clinical Neuroscience, King's College London (A.A.-C.); Department of Neurology (A.A.-C.), King's College Hospital, London, UK; Department of Neurosciences (P.V.D.), Laboratory for Neurobiology, KU Leuven and Center for Brain &amp; Disease Research, VIB, Leuven Brain Institute; Department of Neurology (P.V.D.), University Hospitals Leuven, Belgium; Department of Neurology (O.H.), National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland; FutureNeuro SFI Research Centre (O.H.), Royal College of Surgeons in Ireland, Dublin; and Department of Neuroscience (P.J.S., C.J.M.), Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34315786</ArticleId><ArticleId IdType="pmc">PMC8456357</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000012545</ArticleId><ArticleId IdType="pii">WNL.0000000000012545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127-1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020;167:107986.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062193</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, et al. . Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92(14):e1610-e1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Kliest T, McDermott CJ, et al. . TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Frontotemporal Degener. 2020(7-8);21:496-501.</Citation><ArticleIdList><ArticleId IdType="pubmed">32643415</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Westeneng HJ, Nikolakopoulos S, et al. . Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451-e460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Taylor AA, Beaulieu D, et al. . Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol. 2018;5(4):474-485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899911</ArticleId><ArticleId IdType="pubmed">29687024</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Nikolakopoulos S, Ferguson TA, Liu D, Eijkemans MJC, van den Berg LH. Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs. J Clin Epidemiol. 2018;98:80-88.</Citation><ArticleIdList><ArticleId IdType="pubmed">29486281</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Canosa A, Gallo S, et al. . ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology. 2011;77(15):1432-1437.</Citation><ArticleIdList><ArticleId IdType="pubmed">21956723</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothwell PM. External validity of randomised controlled trials: &#x201c;to whom do the results of this trial apply?&#x201d; Lancet. 2005;365(9453):82-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639683</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Nikolakopoulos S, Roes KCB, et al. . Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2019;90(12):1331-1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902062</ArticleId><ArticleId IdType="pubmed">31292200</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld GJ, Veldink JH, van der Tweel I, et al. . A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53(4):437-445.</Citation><ArticleIdList><ArticleId IdType="pubmed">12666111</ArticleId></ArticleIdList></Reference><Reference><Citation>UKMND-LiCALS Study Group, Morrison KE, Dhariwal S, Hornabrook R, et al. . Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(4):339-345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610091</ArticleId><ArticleId IdType="pubmed">23453347</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepers S, Veldink JH, de Jong SW, et al. . Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol. 2009;66(2):227-234.</Citation><ArticleIdList><ArticleId IdType="pubmed">19743466</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, Veldink JH, Huisman MH, et al. . Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry. 2012;83(5):557-564.</Citation><ArticleIdList><ArticleId IdType="pubmed">22378918</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, Genge A, van den Berg LH, et al. . Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):208-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">28139349</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Yerramilli-Rao P, Szymonifka J, et al. . Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology. 2013;81(15):1350-1355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806927</ArticleId><ArticleId IdType="pubmed">24005339</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. . Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423-433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Eijkemans MJC, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333-341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865572</ArticleId><ArticleId IdType="pubmed">29593436</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, He B, Zhang Y, et al. . Prognostic models for amyotrophic lateral sclerosis: a systematic review. J Neurol. Epub 2021 Mar 10.</Citation><ArticleIdList><ArticleId IdType="pubmed">33694050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Brayne C, et al. . The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88(7):557-563.</Citation><ArticleIdList><ArticleId IdType="pubmed">28285264</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Swash M. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? Arch Neurol. 2006;63(4):557-560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ard MC, Edland SD. Power calculations for clinical trials in Alzheimer's disease. J Alzheimers Dis. 2011;26(suppl 3):369-377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568927</ArticleId><ArticleId IdType="pubmed">21971476</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, et al. . Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12(11):1059-1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Bruijn LI, Shefner JM. ALS drug development guidances and trial guidelines: consensus and opportunities for alignment. Neurology. 2019;93(2):66-71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6656654</ArticleId><ArticleId IdType="pubmed">31171646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J. Statistical Methods for Survival Trial Design: With Applications to Cancer Clinical Trials Using R. Taylor &amp; Francis; 2018.</Citation></Reference><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, et al. . The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982;1(2):121-129.</Citation><ArticleIdList><ArticleId IdType="pubmed">7187087</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics. 1982;38(1):163-170.</Citation><ArticleIdList><ArticleId IdType="pubmed">7082758</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel UR, Jensen K, Karapanagiotou-Schenkel I, Kieser M. Some issues of sample size calculation for time-to-event endpoints using the Freedman and Schoenfeld formulas. J Biopharm Stat. 2015;25(6):1285-1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">25629760</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolakopoulos S, Roes KC, van der Lee JH, van der Tweel I. Sample size calculations in pediatric clinical trials conducted in an ICU: a systematic review. Trials. 2014;15:274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107993</ArticleId><ArticleId IdType="pubmed">25004909</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavernier E, Giraudeau B. Sample size calculation: inaccurate a priori assumptions for nuisance parameters can greatly affect the power of a randomized controlled trial. PLoS One. 2015;10(7):e0132578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501786</ArticleId><ArticleId IdType="pubmed">26173007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachin JM. Maximum information designs. Clin Trials 2005;2(5):453-464.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315649</ArticleId></ArticleIdList></Reference><Reference><Citation>Freidlin B, Othus M, Korn EL. Information time scales for interim analyses of randomized clinical trials. Clin Trials. 2016;13(4):391-399.</Citation><ArticleIdList><ArticleId IdType="pubmed">27136947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Boucher H, Tsiatis AA. Design and analysis of group sequential logrank tests in maximum duration versus information trials. Biometrics. 1995;51(3):988-1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">7548714</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld GJ, van der Tweel I, Wokke JH, van den Berg LH. Sequential designs for clinical trials in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2004;5(4):202-207.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim k, DeMets DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika. 1987;74(1):149-154.</Citation></Reference><Reference><Citation>Hardiman O, van den Berg LH. Edaravone: a new treatment for ALS on the horizon? Lancet Neurol. 2017;16(7):490-491.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JP, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. Am J Epidemiol. 1998;148(11):1117-1126.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahan BC, Jairath V, Dore CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014;15:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022337</ArticleId><ArticleId IdType="pubmed">24755011</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. . The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):162-168.</Citation><ArticleIdList><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>